Cargando…

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy

BACKGROUND: Nephropathy is an important feature of classical Fabry disease, which results in alpha-galactosidase A deficiency and cellular globotriaosylceramide accumulation. We report the safety and efficacy of antiproteinuric therapy with ACE inhibitors or angiotensin II receptor blockers (ARBs) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warnock, David G, Thomas, Christie P, Vujkovac, Bojan, Campbell, Ruth C, Charrow, Joel, Laney, Dawn A, Jackson, Leslie L, Wilcox, William R, Wanner, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Phenotypes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717450/ https://www.ncbi.nlm.nih.gov/pubmed/26490103 http://dx.doi.org/10.1136/jmedgenet-2015-103471

Ejemplares similares

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
por: Warnock, David G., et al.
Publicado: (2012)

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease
por: Keber, Tajda, et al.
Publicado: (2017)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
por: Arends, Maarten, et al.
Publicado: (2018)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
por: Pisani, Antonio, et al.
Publicado: (2015)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
por: Cybulla, Markus, et al.
Publicado: (2022)

Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup
por: Germain, Dominique P, et al.
Publicado: (2020)

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
por: Nowak, Albina, et al.
Publicado: (2022)

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
por: Tsuboi, Kazuya, et al.
Publicado: (2012)

Biomarkers of Fabry Nephropathy: Review and Future Perspective
por: Levstek, Tina, et al.
Publicado: (2020)

CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
Publicado: (2012)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
por: van Kuilenburg, André B. P., et al.
Publicado: (2023)

Letter concerning “Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha”, by Tanaka et al.
por: Linthorst, Gabor E., et al.
Publicado: (2010)

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
por: Smid, Bouwien E, et al.
Publicado: (2011)

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α
por: Tsuboi, Kazuya, et al.
Publicado: (2014)

Agalsidase alfa (Replagal(™)) in the treatment of Anderson-Fabry disease
por: Pastores, Gregory M
Publicado: (2007)

Update on role of agalsidase alfa in management of Fabry disease
por: Ramaswami, Uma
Publicado: (2011)

Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy
por: Levstek, Tina, et al.
Publicado: (2023)

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype
por: Hopkin, Robert J., et al.
Publicado: (2020)

Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6
por: Tezenas du Montcel, Sophie, et al.
Publicado: (2014)

Expansion of the clinical phenotype associated with mutations in activity-dependent neuroprotective protein
por: Pescosolido, Matthew F, et al.
Publicado: (2014)

Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses
por: Tashkin, Donald P., et al.
Publicado: (2014)

A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia
por: Tsoi, Ho, et al.
Publicado: (2014)

Alternative splicing modifies the effect of mutations in COL11A1 and results in recessive type 2 Stickler syndrome with profound hearing loss
por: Richards, Allan J, et al.
Publicado: (2013)

Clinical features for diagnosis and management of patients with PRDM12 congenital insensitivity to pain
por: Zhang, Stella, et al.
Publicado: (2016)

PURA syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review of published literature
por: Reijnders, Margot R F, et al.
Publicado: (2018)

Retrospective natural history of thymidine kinase 2 deficiency
por: Garone, Caterina, et al.
Publicado: (2018)

Variable expression of subclinical phenotypes instead of reduced penetrance in families with mild triphalangeal thumb phenotypes
por: Potuijt, Jacob W P, et al.
Publicado: (2020)

Update and audit of the St George’s classification algorithm of primary lymphatic anomalies: a clinical and molecular approach to diagnosis
por: Gordon, Kristiana, et al.
Publicado: (2020)

Expanding the phenotype of COPA syndrome: a kindred with typical and atypical features
por: Taveira-DaSilva, Angelo M, et al.
Publicado: (2019)

Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency
por: Chirita-Emandi, Adela, et al.
Publicado: (2021)

De novo TRPV4 Leu619Pro variant causes a new channelopathy characterised by giant cell lesions of the jaws and skull, skeletal abnormalities and polyneuropathy
por: Ragamin, Aviel, et al.
Publicado: (2022)

Phenotypes in adult patients with Rett syndrome: results of a 13-year experience and insights into healthcare transition
por: Peron, Angela, et al.
Publicado: (2022)

Clinical and molecular features of 66 patients with musculocontractural Ehlers−Danlos syndrome caused by pathogenic variants in CHST14 (mcEDS-CHST14)
por: Minatogawa, Mari, et al.
Publicado: (2022)

Redefining WILD syndrome: a primary lymphatic dysplasia with congenital multisegmental lymphoedema, cutaneous lymphovascular malformation, CD4 lymphopaenia and warts
por: Mansour, Sahar, et al.
Publicado: (2023)

Clinical diversity and molecular mechanism of VPS35L-associated Ritscher-Schinzel syndrome
por: Otsuji, Shiomi, et al.
Publicado: (2023)

Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine: A case report
por: Kanai, Takahiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dgakm6e1n2rsf9r25dbufrkv4c